Factory directly supply Vancomycin Type Of Antibiotic - Other Protected Amino Acids for Disulfide bond – Gentolex
Factory directly supply Vancomycin Type Of Antibiotic - Other Protected Amino Acids for Disulfide bond – Gentolex Detail:
Product Detail
|
NO |
Products |
CAS No |
Application |
Key Quality Indicator |
||||
|
Purity |
Isomer |
Specific impurity |
*Max1 |
Moisture |
||||
|
1 |
Fmoc-Cys(Acm)-OH |
86060-81-3 |
Disulfide bond |
≥99.0% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
2 |
Fmoc-Cys(Mmt)-OH |
177582-21-7 |
Disulfide bond |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
3 |
Fmoc-Cys(4-allylbutyrate)-OH |
/ |
Disulfide bond |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
4 |
Mpa(Trt)-OH |
27144-18-9 |
End of sequence |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
5 |
Fmoc-Thr(tBu)-OL |
189337-28-8 |
Octreotide |
≥97.0% |
≤0.3% |
≤0.5% |
≤1.0% |
≤1.0% |
|
6 |
Fmoc-D-Arg(pbf)-OH |
187618-60-6 |
Desmopressin |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤2.0% |
|
7 |
Fmoc-Gly-Gly-OH |
35665-38-4 |
Bivalirudin |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
8 |
Fmoc-Gly-Gly-Gly-OH |
170941-79-4 |
Terlipressin |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
9 |
Fmoc-Gly-Gly-Gly-Gly-OH |
/ |
Bivalirudin |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
10 |
Fmoc-Gly-Asp(tBu)-OH |
/ |
Bivalirudin |
≥99.5% |
/ |
≤0.15% |
≤0.2% |
≤1.0% |
|
11 |
Boc-Cys(Trt)-OH |
21947-98-8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
12 |
Boc-Arg(pbf)-OH |
200124-22-7 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
13 |
Boc-Ala-OH |
15761-38-3 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
14 |
Boc-D-Phe-OH |
18942-49-9 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
15 |
Boc-Gly-OH |
4530-20-5 |
End of sequence |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
16 |
Boc-Lys(Boc)-OH.DCHA |
15098-69-8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
17 |
Boc-Ser(tBu)-OH |
7738-22-9 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
18 |
Boc-Thr(tBu)-OH |
13734-40-2 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
19 |
Boc-D-Ala-OH |
7764-95-6 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
20 |
Boc-Met-OH |
2488-15-5 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
21 |
Boc-Tyr(tBu)-OH |
47375-34-8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
22 |
Boc-D-Arg(pdf)-OH |
187618-60-6 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
23 |
Boc-Asp(OtBu)-OH.DCHA |
1913/12/8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
24 |
Fmoc-HomoArg(pbf)-OH |
1159680-21-3 |
Eptifibatide |
≥98.5% |
≤0.2% |
/ |
≤0.5% |
≤2.0% |
|
25 |
Fmoc-Asp-OtBu |
129460-09-9 |
Thymalfasin |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
26 |
Fmoc-Tyr(Me)-OH |
77128-72-4 |
Carbetocin |
≥98.5% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
27 |
Fmoc-Orn(Boc)-OH |
109425-55-0 |
Atosiban Omnipressin Daptomycin |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤2.0% |
|
28 |
Fmoc-D-Tyr(Et)-OH |
162502-65-0 |
Atosiban |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
29 |
Fmoc-Asp(OAll)-OH |
146982-24-3 |
Melanotan |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
30 |
Ac-Nle-OH |
15891-49-3 |
Melanotan |
≥99.0% |
/ |
≤0.3% |
≤0.3% |
≤1.0% |
|
31 |
Fmoc-Nle-OH |
77284-32-3 |
Melanotan Afamelanotide |
≥99.0% |
/ |
≤0.3% |
≤0.3% |
≤1.0% |
|
32 |
Ac-Glu(OtBu)-OH |
84192-88-1 |
Argireline Acetyl octapeptide-3 |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
33 |
Ac-β-Ala-OH·DCHA |
/ |
Acetyl tetrapeptide-5 |
≥99.0% |
/ |
≤0.3% |
≤0.3% |
≤1.0% |
|
34 |
Fmoc-ß-Ala-OH |
35737-10-1 |
Acetyl tetrapeptide-5 |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
35 |
Fmoc-Hyp(tBu)-OH |
122996-47-8 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
36 |
Fmoc-Thi-OH |
130309-35-2 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
37 |
Fmoc-D-Tic-OH |
130309-33-0 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
38 |
Fmoc-Oic-OH |
130309-37-4 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
39 |
Boc-Sar-OH |
13734-36-6 |
Saralasin |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
40 |
Fmoc-Sar-OH |
77128-70-2 |
Saralasin |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
41 |
Fmoc-Tyr(SO3Na)-OH.H2O |
106864-37-3 |
Sincalide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
42 |
Fmoc-D-Asp(OtBu)-OH |
112883-39-3 |
Daptomycin |
≥98.5% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
43 |
Ac-Ser(tBu)-OH |
77285-09-7 |
Afamelanotide |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
44 |
Boc-HomoCys(Trt)-OH |
201419-16-1 |
Depreotide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
45 |
Fmoc-HomoCys(Trt)-OH |
167015-23-8 |
Depreotide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
46 |
Fmoc-Dab-OH |
161420-87-7 |
Snake venom |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
*Max1 = Max Unknown Purity
Other Indicator:
- Acetic Acid: ≤0.02% (All Products)
- Ethyl Acetate: ≤0.5% (All Products)
- Alcohol: ≤0.5% (All Products)
- Max Unknow Impurity: Fmoc-Trp(Boc)-OH (143824-78-6) ≤0.3%; Others ≤0.2%
Product detail pictures:
Related Product Guide:
To meet the customers' over-expected pleasure , we have now our solid crew to supply our greatest all round assistance which includes marketing, sales, planning, production, top quality controlling, packing, warehousing and logistics for Factory directly supply Vancomycin Type Of Antibiotic - Other Protected Amino Acids for Disulfide bond – Gentolex , The product will supply to all over the world, such as: Uzbekistan, Cape Town, Tunisia, Strong infrastructure is the need of any organization. We are backed with a robust infrastructural facility that enables us to manufacture, store, quality check and dispatch our products worldwide. To maintain smooth work flow, we have sectioned our infrastructure into a number of departments. All these departments are functional with latest tools, modernized machines and equipment. Owing to which, we are able to accomplish voluminous production without compromising upon the quality.
By Sara from Hyderabad - 2018.10.31 10:02
This supplier's raw material quality is stable and reliable, has always been in accordance with the requirements of our company to provide the goods that quality meet our requirements.
By ron gravatt from Korea - 2018.09.23 17:37
